Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Return of the Switch? A Fallow 2005 Sowed the Seeds for Future Switches

This article was originally published in The Tan Sheet

Executive Summary

A Building Yea

You may also be interested in...



Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation

Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD

FDA Mevacor OTC Switch Answer: Signs Point To “Not Approvable”

FDA appears to have issued a "not approvable" letter in response to J&J/Merck's application to switch the cholesterol-lowering drug Mevacor (lovastatin 20 mg) over the counter

OTC Statins: What We Have Is A Failure To Communicate

The immediate prospects for an OTC statin may have been dampened by the lopsided Mevacor panel vote, but persistent enthusiasm among core decision-makers offers optimism in the long term

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel